LONDON, March 01, 2018 -- The global clinical genomics market will grow at a CAGR of 22.1% during the forecast period to reach USD 1,305.1 million by 2023, primarily driven by “growing significance of early disease detection and prevention, rising insistence for precision medicine, increasing application of genetic testing in oncology, and favourable reimbursement scenario related to genetic testing”, Meticulous Research™ noted in a press release today.
The global clinical genomics market is mainly segmented by test type (diagnostic testing, genetic testing, newborn screening, prenatal testing, preimplantation testing, carrier screening and other tests), software, method (molecular tests, chromosomal tests, biochemical tests), end user (hospitals & clinics, government laboratories & research centers, academics and research institutes and other end users), and geography.
The report notes that, based on methods the molecular tests held the largest share, owing to “the advancement in technology, which helps to detect the single nucleotide resolution with cheaper, faster, and with utmost accuracy by using WGS and WES technologies.”
Request Sample Report: https://www.meticulousresearch.com/request-sample-report/?cp_id=3763
Geographically, the global clinical genomics market is segmented into four major regions, namely North America, Europe, Asia-Pacific, and Rest of World. North America accounted for the major share of this market in 2017, followed by Europe and Asia-Pacific region. The major share of the North American region is mainly attributed to “the high burden of chronic and infectious diseases, increasing R&D expenditure, and various government initiatives”. However, the Asia-Pacific region is projected to grow at fastest CAGR during the forecast period, due to “increasing population, rising prevalence of various diseases, availability of funding, and developing healthcare infrastructures in the region”.
Browse report: https://www.meticulousresearch.com/product/clinical-genomics-market-forecast-2023/
The key players in the clinical genomics market are Quest Diagnostics Incorporated, Eurofins Scientific SE, Illumina, Inc., PerkinElmer, Inc., NeoGenomics Inc., Foundation Medicine, Inc., Rosetta Genomics Ltd., Invitae Corporation, Myriad Genetics, Inc., Natera, Inc., Genomic Health, Inc., OPKO Health, Inc., Centogene AG, Clinical Genomics Pty Ltd., 23andMe, Inc., Iverson Genetic Diagnostics, Inc., Veritas Genetics, Gene by Gene, Ltd., GenomeDx Biosciences, Inc., MedGenome, Strand Life Sciences Pvt. Ltd., Beijing Genomics Institute (BGI), Retrogen, Inc., Personalis, Inc., PathGroup.
Enquire before buying: https://www.meticulousresearch.com/enquire-before-buying/?cp_id=3763
Contact:
Viren Shrivastava
Email: [email protected]
Direct Lines: +1-646-781-8004 (North America)
+44-203-868-8738 (Europe)
+91 744-7780008 (Asia-Pacific)


Shein Shares Drop 5% After Weak Hong Kong IPO Debut
South Korea, US Discuss Chip Investments Amid Tariff Plans
Xiaomi Shares Jump on Europe EV Expansion Plan
Anthropic IPO Marketing Expected to Start in Mid-October
ByteDance Secures $29.6 Billion Loan to Boost AI Investment
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations
Audi, SAIC Launch China Innovation Hub for New AUDI Models
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns
OpenAI Nears Astra AI Model Launch With Safety Focus
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 



